ZA201703764B - Formulations of a pi3k/mtor-inhibitor for intravenous administration - Google Patents

Formulations of a pi3k/mtor-inhibitor for intravenous administration

Info

Publication number
ZA201703764B
ZA201703764B ZA201703764A ZA201703764A ZA201703764B ZA 201703764 B ZA201703764 B ZA 201703764B ZA 201703764 A ZA201703764 A ZA 201703764A ZA 201703764 A ZA201703764 A ZA 201703764A ZA 201703764 B ZA201703764 B ZA 201703764B
Authority
ZA
South Africa
Prior art keywords
pi3k
mtor
formulations
inhibitor
intravenous administration
Prior art date
Application number
ZA201703764A
Other languages
English (en)
Inventor
Kevin Richard Back
Michael Cram
Aidan James Harper
W James Huang
Jonathan Richard Lillis
Timothy Michael Lukas
Sumit Luthra
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of ZA201703764B publication Critical patent/ZA201703764B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/17Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355Non-condensed oxazines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA201703764A 2014-12-17 2017-06-01 Formulations of a pi3k/mtor-inhibitor for intravenous administration ZA201703764B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462093060P 2014-12-17 2014-12-17
US201562250633P 2015-11-04 2015-11-04
PCT/IB2015/059515 WO2016097949A1 (en) 2014-12-17 2015-12-10 Formulations of a pi3k/mtor-inhibitor for intravenous administration

Publications (1)

Publication Number Publication Date
ZA201703764B true ZA201703764B (en) 2020-11-25

Family

ID=54937330

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA201703764A ZA201703764B (en) 2014-12-17 2017-06-01 Formulations of a pi3k/mtor-inhibitor for intravenous administration

Country Status (25)

Country Link
US (2) US10172942B2 (https=)
EP (1) EP3233054B1 (https=)
JP (1) JP6420753B2 (https=)
KR (1) KR102016822B1 (https=)
CN (1) CN107205923B (https=)
AU (1) AU2015365497B2 (https=)
CA (1) CA2915199C (https=)
CY (1) CY1124527T1 (https=)
DK (1) DK3233054T3 (https=)
ES (1) ES2881214T3 (https=)
HR (1) HRP20211446T1 (https=)
HU (1) HUE055928T2 (https=)
IL (1) IL252158B (https=)
LT (1) LT3233054T (https=)
MX (1) MX380172B (https=)
NZ (1) NZ731518A (https=)
PL (1) PL3233054T3 (https=)
PT (1) PT3233054T (https=)
RS (1) RS62337B1 (https=)
RU (1) RU2672875C1 (https=)
SG (1) SG11201703826TA (https=)
SI (1) SI3233054T1 (https=)
TW (1) TWI660729B (https=)
WO (1) WO2016097949A1 (https=)
ZA (1) ZA201703764B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS62663B1 (sr) 2017-08-25 2021-12-31 Pfizer Farmaceutska vodena formulacija koja sadrži 1-(4-{[4-(dimetilamino)piperidin-1-il]karbonil}fenil)-3-[4-(4,6-dimorfolin-4-il-1,3,5-triazin-2-il)fenil]ureu
MX2020013238A (es) * 2018-06-07 2021-02-22 Pfizer Formulacion acuosa que comprende 1-(4-{[4-(dimetilamino)piperidin- 1-il]carbonil}fenil)-3-[4-(4,6-dimorfolin-4-il-1,3,5-triazin-2-il )fenil]urea.
WO2023009438A1 (en) 2021-07-26 2023-02-02 Celcuity Inc. 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea (gedatolisib) and its combinations for use in the treatment of cancer
WO2025128712A1 (en) 2023-12-12 2025-06-19 Celcuity Inc. Treatment of ocular diseases using 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl)phenyl)-3-[4-(4,6- dimorpholin-4- yl-1,3,5-triazin-2-yl)phenyl]urea
US20260053814A1 (en) 2024-08-21 2026-02-26 Celcuity Inc. Treatment regimens for gedatolisib in hormonally-driven disorders

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0852951A1 (de) * 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
KR20080018908A (ko) * 2005-05-27 2008-02-28 바이엘 헬스케어 아게 암 치료용 디아릴 우레아 화합물 및 pi3, akt 키나제또는 mtor 억제제 (라파마이신)를 포함하는 병용요법
US20080234262A1 (en) * 2007-03-21 2008-09-25 Wyeth Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors
DE202008001253U1 (de) * 2008-01-28 2008-04-10 Mirror Image Ag Bildanzeigegerät
AP2775A (en) 2008-05-23 2013-09-30 Wyeth Llc Triazine compounds as P13 kinase and MTOR inhibitors
JP2011521968A (ja) * 2008-05-30 2011-07-28 ジェネンテック, インコーポレイテッド プリンpi3k阻害剤化合物および使用方法
WO2010096619A1 (en) * 2009-02-23 2010-08-26 Wyeth Llc Process, purification and crystallization of 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea
WO2014078522A1 (en) * 2012-11-14 2014-05-22 Ohio State Innovation Foundation Materials and methods useful for treating glioblastoma
EP2968191B1 (en) * 2013-03-14 2021-06-16 Abraxis BioScience, LLC Methods of treating bladder cancer
MA39734B1 (fr) * 2014-03-14 2019-07-31 Pfizer Nanoparticules thérapeutiques comportant un agent thérapeutique, et leurs procédés de fabrication et d'utilisation

Also Published As

Publication number Publication date
HRP20211446T1 (hr) 2021-12-24
EP3233054A1 (en) 2017-10-25
BR112017010841A2 (pt) 2017-12-26
ES2881214T3 (es) 2021-11-29
EP3233054B1 (en) 2021-06-30
SI3233054T1 (sl) 2021-11-30
AU2015365497A1 (en) 2017-06-01
TWI660729B (zh) 2019-06-01
TW201632188A (zh) 2016-09-16
RS62337B1 (sr) 2021-10-29
MX380172B (es) 2025-03-12
LT3233054T (lt) 2021-07-26
CN107205923B (zh) 2021-03-05
AU2015365497B2 (en) 2020-07-02
US20190105390A1 (en) 2019-04-11
CN107205923A (zh) 2017-09-26
SG11201703826TA (en) 2017-07-28
JP6420753B2 (ja) 2018-11-07
IL252158B (en) 2021-01-31
WO2016097949A1 (en) 2016-06-23
JP2016113461A (ja) 2016-06-23
US10660959B2 (en) 2020-05-26
IL252158A0 (en) 2017-07-31
RU2672875C1 (ru) 2018-11-20
CA2915199C (en) 2018-11-06
CY1124527T1 (el) 2022-07-22
NZ731518A (en) 2019-03-29
MX2017008072A (es) 2017-09-28
PT3233054T (pt) 2021-08-02
PL3233054T3 (pl) 2021-12-20
KR102016822B1 (ko) 2019-08-30
DK3233054T3 (da) 2021-08-02
CA2915199A1 (en) 2016-06-17
KR20170082638A (ko) 2017-07-14
US20170360935A1 (en) 2017-12-21
HUE055928T2 (hu) 2022-01-28
US10172942B2 (en) 2019-01-08

Similar Documents

Publication Publication Date Title
DK3236943T3 (da) Sammensætninger til ileo-jejunal lægemiddeladministration
IL278034B (en) Proton binding polymers for oral administration
IL251726A0 (en) Viscosity reduction of pharmaceutical preparations
PL3237045T3 (pl) Urządzenie do podawania produktów leczniczych
PL3191167T3 (pl) Zawór do podawania płynnych leków
ZA201605263B (en) Pharmaceutical composition for topical administration
ZA201401683B (en) Pharmaceutical compositions for rectal administration
EP3256133A4 (en) Intravenous infusion dosage form
PT3191168T (pt) Válvula para administração de vários fluidos medicamentosos
ZA201703562B (en) Pharmaceutical composition for oral administration comprising taxane
LT3226888T (lt) Selektyvaus il-6-trans-signalinio inhibitoriaus skyrimas
IL255853B (en) Nano-particles for use as a therapeutic vaccine
ZA201703764B (en) Formulations of a pi3k/mtor-inhibitor for intravenous administration
HRP20181968T1 (hr) Formulacije temeljene na melatoninu za parenteralno davanje
ZA201608785B (en) Nasal administration
GB201419540D0 (en) Delivery of drugs
EP3355888B8 (en) Hemi-synthetic trilobine analogs for use as a drug
GB201417589D0 (en) Pharmaceutical Formulations
PH32014000630S1 (en) Syringe for oral medication
HK1229386A1 (en) Administration regime
GB201403532D0 (en) Intravenous cannula
GB201407741D0 (en) Novel drug formulation
ZA201405476B (en) Anthelmintic medicament
GB201400951D0 (en) Novel drug formulation